☰

Dejan Knezevic, Ph.D. - Publications

Affiliations: 
2005 Yale University, New Haven, CT 
Area:
Cell Biology, Genetics, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Cullen J, Lynch J, Klein E, Eeden SVD, Carroll P, Mohler J, Lu R, Knezevic D, Lawrence HJ. Mp67-10 A 17-Gene Genomic Assay As A Predictor Of Outcomes In African Americans With Prostate Cancer The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000947.010  0.35
2018 Magi-Galluzzi C, Isharwal S, Falzarano SM, Tsiatis A, Dee A, Maddala T, Knezevic D, Febbo PG, Lawrence J, Klein EA. The 17-gene Genomic Prostate Score Assay Predicts Outcome after Radical Prostatectomy Independent of PTEN Status. Urology. PMID 30142405 DOI: 10.1016/J.Urology.2018.07.018  0.385
2018 Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A. Validation of the 16-Gene Recurrence Score in patients with locoregional, high-risk renal cell carcinoma from a phase 3 trial of adjuvant sunitinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29773662 DOI: 10.1158/1078-0432.Ccr-18-0323  0.342
2017 Escudier BJ, Rini BI, Martini J, Chang WY, Breza J, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, English PA, Li R, Lin X, Valota O, Cartenì G, et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. Journal of Clinical Oncology. 35: 4508-4508. DOI: 10.1200/Jco.2017.35.15_Suppl.4508  0.331
2016 Magi-Galluzzi C, Maddala T, Falzarano SM, Cherbavaz DB, Zhang N, Knezevic D, Febbo PG, Lee M, Lawrence HJ, Klein EA. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. Oncotarget. PMID 27121323 DOI: 10.18632/Oncotarget.8944  0.384
2016 Magi-Galluzzi C, Bonham M, Tsiatis A, Falzarano S, Dee A, Maddala T, Knezevic D, Febbo P, Lawrence HJ, Klein E. Mp02-19 Biomarkers Of Biochemical (Bcr) And Clinical Recurrence (Cr) In Prostate Cancer (Pca) Following Radical Prostatectomy (Rp) – Performance Of A 17-Gene Genomic Prostate Score (Gps) And Tests For Pten Loss. The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1891  0.375
2015 Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, Svedman C, Martini JF, Williams JA, Verkarre V, Radulescu C, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. The Lancet. Oncology. 16: 676-85. PMID 25979595 DOI: 10.1016/S1470-2045(15)70167-1  0.349
2015 Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. European Urology. 68: 123-31. PMID 25465337 DOI: 10.1016/J.Eururo.2014.11.030  0.38
2015 Cullen J, Rosner IL, Brand TC, Ali A, Chen Y, Zhang N, Tsiatis AC, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn I, Mcleod DG. The association of a 17-gene genomic prostate score with adverse surgical pathology and recurrence following surgery for localized prostate cancer (PCa): A comparison of African American and Caucasian patients. Journal of Clinical Oncology. 33: 86-86. DOI: 10.1200/Jco.2015.33.7_Suppl.86  0.38
2015 Escudier BJ, Koscielny S, Maddala T, Svedman C, Verkarre V, Radulescu C, Neuzillet Y, Timsit MO, Hemmerle I, Tsiatis AC, Bonham M, Knezevic D, Martini J, Williams JA, Lebret T, et al. Robustness of the 16-gene signature for prediction of recurrence-free interval in localized clear cell renal cell carcinoma. Journal of Clinical Oncology. 33: 455-455. DOI: 10.1200/Jco.2015.33.7_Suppl.455  0.374
2015 Knezevic D, Lu R, Burke E, Rothney M, Zhang N, Febbo PG, Lawrence HJ. Evaluation of the contribution of individual gene groups to a 17-gene prognostic prostate cancer signature. Journal of Clinical Oncology. 33: 101-101. DOI: 10.1200/Jco.2015.33.7_Suppl.101  0.396
2015 Cullen J, Sesterhenn I, Klein E, Mohler J, Carroll P, Cooperberg M, Zhang N, Maddala T, Knezevic D, Tsiatis A, Lawrence HJ, Febbo P. Mp1-05 A Multi-Center Comparison Of A 17-Gene Genomic Prostate Score (Gps) As A Predictor Of Outcomes In African-American (Aa) And Caucasian (Ca) Men With Clinically Localized Prostate Cancer (Pca) The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.168  0.372
2014 Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. European Urology. 66: 550-60. PMID 24836057 DOI: 10.1016/J.Eururo.2014.05.004  0.369
2014 Escudier BJ, Koscielny S, Lopatin M, Svedman C, Verkarre V, Radulescu C, Neuzillet Y, Hemmerle I, Timsit MO, Tsiatis AC, Bonham M, Knezevic D, Lebret T, Goddard AD, Arnaud M. Validation of a 16-gene signature for prediction of recurrence after nephrectomy in stage I-III clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology. 32: 4502-4502. DOI: 10.1200/Jco.2014.32.15_Suppl.4502  0.383
2013 Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. Bmc Genomics. 14: 690. PMID 24103217 DOI: 10.1186/1471-2164-14-690  0.379
2013 Klein EA, Falzarano SM, Zhang N, Knezevic D, Maddala T, Lawrence HJ, Cherbavaz DB, Pelham RJ, Millward C, Lee M, Magi-Galluzzi C. Evidence for a field effect in early prostate cancer (PCa): Gene expression profiles in normal-appearing prostate tissue (NT) adjacent to tumor (T) as predictors of clinical outcome. Journal of Clinical Oncology. 31: 5029-5029. DOI: 10.1200/Jco.2013.31.15_Suppl.5029  0.389
2013 Cooperberg M, Simko J, Falzarano S, Maddala T, Chan J, Cowan J, Magi-Galluzzi C, Tsiatis A, Tenggara-Hunter I, Knezevic D, Baehner F, Kattan M, Shak S, Lee M, Klein E, et al. 2131 Development And Validation Of The Biopsy-Based Genomic Prostate Score (Gps) As A Predictor Of High Grade Or Extracapsular Prostate Cancer To Improve Patient Selection For Active Surveillance The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2040  0.376
2012 Klein EA, Maddala T, Millward C, Cherbavaz DB, Falzarano SM, Knezevic D, Novotny WF, Lee M, Magi-Galluzzi C. Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer. Journal of Clinical Oncology. 30: 4560-4560. DOI: 10.1200/Jco.2012.30.15_Suppl.4560  0.4
2011 Campbell S, Knezevic D, Maddala T, Novotny WF, Zhou M, Aydin H, Elson P, Parodi L, Goddard AD, Rini BI. Role of quantitative gene expression using RT-PCR in the prediction of recurrence risk in resected T1 clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 338. PMID 27968616 DOI: 10.1200/Jco.2011.29.7_Suppl.338  0.361
2010 Rini BI, Zhou M, Aydin H, Elson P, Maddala T, Knezevic D, Parodi L, Bukowski RM, Novotny WF, Cowens JW. Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology. 28: 4501-4501. DOI: 10.1200/Jco.2010.28.15_Suppl.4501  0.304
2008 Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle (Georgetown, Tex.). 7: 1604-12. PMID 18520179 DOI: 10.4161/Cc.7.11.5929  0.376
2007 Knezevic D, Zhang W, Rochette PJ, Brash DE. Bcl-2 is the target of a UV-inducible apoptosis switch and a node for UV signaling. Proceedings of the National Academy of Sciences of the United States of America. 104: 11286-91. PMID 17586682 DOI: 10.1073/Pnas.0701318104  0.596
2006 Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, Heimbrook DC, Chen L. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proceedings of the National Academy of Sciences of the United States of America. 103: 10660-5. PMID 16818887 DOI: 10.1073/Pnas.0600447103  0.342
2004 Knezevic D, Brash DE. Role of E2F1 in apoptosis: a case study in feedback loops. Cell Cycle (Georgetown, Tex.). 3: 729-32. PMID 15107604 DOI: 10.4161/Cc.3.6.907  0.591
2003 Wikonkal NM, Remenyik E, Knezevic D, Zhang W, Liu M, Zhao H, Berton TR, Johnson DG, Brash DE. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nature Cell Biology. 5: 655-60. PMID 12833065 DOI: 10.1038/Ncb1001  0.596
Show low-probability matches.